Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Max Kates MD

Max Kates MD

Assistant Professor of Urology and Oncology, James Buchanan Brady Urological Institute, Co-Director, Multidisciplinary Bladder Cancer Clinic, Greenberg Bladder Cancer Institute, Johns Hopkins Hospital, Baltimore, Maryland
Assistant Professor of Urology and Oncology, James Buchanan Brady Urological Institute, Co-Director, Multidisciplinary Bladder Cancer Clinic, Greenberg Bladder Cancer Institute, Johns Hopkins Hospital, Baltimore, MD

Disclosures

Dr. Kates reports the following related disclosure: Part owner of a patent “Methods to achieve enhanced delivery to the bladder”

Recent Contributions to PracticeUpdate:

  1. Outcomes of Sequential Intravesical Gemcitabine and Docetaxel Therapy vs BCG Therapy in Patients With High-Risk Non–Muscle-Invasive Bladder Cancer
  2. Outcomes of En Bloc vs Conventional Transurethral Resection of Bladder Tumors
  3. Time From TURBT to BCG Induction Does Not Impact Outcomes
  4. Optimizing Cystoscopy Timing and Frequency in Intermediate-Risk, Non–Muscle Invasive Bladder Cancer
  5. Safety and Feasibility of Early Single-Dose Mitomycin C Bladder Instillation After Nephroureterectomy
  6. Survival Outcomes of Late Disease Recurrences Following Radical Cystectomy
  7. Bladder Cancer Recurrence Rates and Costs Increased During the BCG Shortage
  8. Continuous Saline Bladder Irrigation After TURBT in Patients With High-Grade Non–Muscle Invasive Bladder Cancer
  9. Can Renal and Bladder Ultrasound Replace CT Urography in Patients Investigated for Microscopic Hematuria?
  10. Very Low–Risk Bladder Cancer—A New Entity?

Recently Updated